ID
11638
Beskrivning
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis ODM derived from http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Länk
http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Nyckelord
Versioner (2)
- 2011-11-24 2011-11-24 -
- 2015-07-09 2015-07-09 - Martin Dugas
Uppladdad den
9 juli 2015
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Psoriasis NCT00216879
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
Beskrivning
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Beskrivning
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
Datatyp
boolean
Alias
- UMLS CUI-1
- C0853073
- UMLS CUI-2
- C0018233
Beskrivning
UVB therapy anywhere on the patient within 14 days prior to randomisation
Datatyp
boolean
Alias
- UMLS CUI-1
- C0564461
Beskrivning
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
Datatyp
boolean
Alias
- UMLS CUI-1
- C0005522
Beskrivning
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
Datatyp
boolean
Alias
- UMLS CUI-1
- C1515119
Beskrivning
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
Datatyp
boolean
Alias
- UMLS CUI-1
- C0150349
Beskrivning
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
Datatyp
boolean
Alias
- UMLS CUI-1
- C0150349
- UMLS CUI-2
- C0001617
Beskrivning
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
Datatyp
boolean
Alias
- UMLS CUI-1
- C2347852
Beskrivning
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
Datatyp
boolean
Alias
- UMLS CUI-1
- C0343052
- UMLS CUI-2
- C0152081
- UMLS CUI-3
- C0748052
Beskrivning
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
Datatyp
boolean
Alias
- UMLS CUI-1
- C0037278
Beskrivning
Known or suspected severe renal insufficiency or severe hepatic disorders
Datatyp
boolean
Alias
- UMLS CUI-1
- C1565489
- UMLS CUI-2
- C1869009
Beskrivning
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
Datatyp
boolean
Alias
- UMLS CUI-1
- C0020437
Beskrivning
Trial subjects should be using an adequate method of contraception
Datatyp
boolean
Alias
- UMLS CUI-1
- C0700589
Similar models
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
C0018233 (UMLS CUI-2)
C0001617 (UMLS CUI-2)
C0152081 (UMLS CUI-2)
C0748052 (UMLS CUI-3)
C1869009 (UMLS CUI-2)